Why Lows Become More Likely

In the early years of LADA, lows are rare. Later they are a routine consideration. Three separate things change, and they compound.

The first is your treatment. Metformin does not cause lows. Sulfonylureas and insulin do. So the risk arrives with the prescription, not with the disease.

The second is your remaining insulin production. A working pancreas fine-tunes itself constantly, releasing less insulin when your glucose drops. That built-in brake is why people with plenty of beta-cell function rarely go low. As those cells are lost, the brake weakens, and injected insulin keeps working regardless of what your glucose is doing.

The third is your body's counter-defence. When glucose falls, the pancreas normally releases glucagon, a hormone that tells the liver to put glucose back into the blood. In long-standing autoimmune diabetes that response becomes blunted, so recovery from a low is slower and less reliable.

There is a further consequence. Repeated lows can dull your warning symptoms, so you stop feeling a low coming until it is already severe. If you notice this happening, tell your doctor — it usually means targets should be loosened for a period to let your warning symptoms return.

The practical response is not to fear insulin, but to expect the risk profile to shift: check more often when treatment changes, always carry glucose, and treat recurring lows as a dosing problem to solve rather than something to tolerate.